Zealand Pharma A/S (ZEAL)
(Delayed Data from NSDQ)
$20.45 USD
+0.29 (1.45%)
Updated May 3, 2019 03:59 PM ET
After-Market: $20.26 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.45 USD
+0.29 (1.45%)
Updated May 3, 2019 03:59 PM ET
After-Market: $20.26 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
by Zacks Equity Research
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?
by Zacks Equity Research
Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
by Zacks Equity Research
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.
Zealand Pharma AS (ZEAL) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
Zealand Pharma AS (ZEAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).
Zealand (ZEAL) Surges: Stock Moves 9.1% Higher
by Zacks Equity Research
Zealand (ZEAL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Zealand Announces Dosing Initiation in Type 2 Diabetes Study
by Zacks Equity Research
Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.
Why Earnings Season Could Be Great for Zealand Pharma (ZEAL)
by Zacks Equity Research
Zealand Pharma (ZEAL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
by Zacks Equity Research
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
Will Zealand Pharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Zealand Pharma.
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.